RxDoctor Payments DataLook up a doctor →

William Harley, MD

Infectious Disease · Charlotte, NCNPI 1467402719

Payments from drug & device makers

$307,244in general payments, 2019–2025

Across 889 payments — averaging $345.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$137K
  • Merck$92K
  • Gilead$68K
  • Viiv Healthcare Company$3K
  • AbbVie$3K
  • Johnson & Johnson$661
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$8,3103%
  • Speaking & faculty fees$227,11374%
  • Travel & lodging$53,14917%
  • Food & beverage$18,2936%
  • Education$3790%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$307,244 in reported general payments places this provider in the 90th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$91,468
Medicare patients
148
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala277$1,127,386
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf33$153,219
OdefseyEmtricitab/Rilpiviri/Tenof Ala42$146,319
DovatoDolutegravir Sodium/Lamivudine34$99,194
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$43,090
Darunavir15$23,767
Daptomycin41$16,860
Etravirine12$12,664
Vancomycin Hcl45$10,933
CeftriaxoneCeftriaxone Sodium80$10,416
ErtapenemErtapenem Sodium15$4,465
Cefazolin Sodium75$3,855
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$1,205
Doxycycline Hyclate33$947
Cephalexin44$935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$68,481$1,170,476288 claims
Janssen Products, LPSymtuza$338$153,21933 claims
Viiv Healthcare CompanyDovato$3,435$99,19434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →